Ulotaront (SEP-363856): A Novel Mechanism Challenging the Status Quo in Schizophrenia Treatment
Schizophrenia is a chronic, severe mental disorder affecting approximately 1% of the global population, characterized by episodes of psychosis, disrupted thought processes, hallucinations, social withdrawal, and profound cognitive impairment. For decades, treatment has relied almost exclusively on antipsychotic drugs that block dopamine D2 receptors — a mechanism that, while effective for positive symptoms like hallucinations, often fails to address negative symptoms such as social isolation and lack of motivation, and carries a heavy burden of metabolic and neurological side effects. Against this backdrop, a new class of compound has emerged to challenge the conventional wisdom of schizophrenia pharmacology. What Is Ulotaront? Ulotaront (SEP-363856) is an investigational oral small molecule developed by Sumitomo Pharma America (SMPA) and Otsuka Pharmaceuticals, discovered in collaboration with PsychoGenics using a mechanism-independent, AI-assisted in vivo phenotypic platform c...